Author + information
- Philipp Rein,
- Daniela Zanolin,
- Andreas Leiherer,
- Alexander Vonbank,
- Christoph H. Saely and
- Heinz Drexel
Background: Pro-B-type natriuretic peptide (proBNP) is a prognostic biomarker in various patient populations. Its power to predict cardiovascular events in metabolic syndrome (MetS) patients undergoing coronary angiography is unclear.
Methods: We therefore measured serum proBNP in 752 patients who underwent coronary angiography for the evaluation of suspected or established coronary artery disease (CAD). Significant CAD was diagnosed in the presence of coronary stenoses with lumen narrowing ≥50%. Presence of the MetS was defined according to the current harmonized consensus definition. Prospectively, we recorded vascular events over 5.1±2.4 years.
Results: ProBNP was significantly higher in patients with (n=591) than in subjects without significant CAD at baseline (715±1361 vs. 652±1842 pg/ml; p=0.003). Prospectively, we recorded 185 cardiovascular events. The incidence of vascular events significantly increased over tertiles of proBNP in patients with the MetS (15.8%, 24.2%, and 60.0% respectively; p=0.033) as well as in subjects without the MetS (13.3%, 22.2%, and 64.4%, respectively; p=0.004). Concordantly, serum proBNP significantly predicted the incidence of cardiovascular events after adjustment for age, gender, BMI, smoking, systolic and diastolic blood pressure, LDL cholesterol, HDL cholesterol and the eGFR both in patients with the MetS (standardized adjusted HR 1.34 [1.14-1.58]; p<0.001) and in subjects without the MetS (HR 1.24 [1.11-1.39]; p<0.001). These results were not attenuated after further adjustment for the angiographically determined baseline CAD state in patients with the MetS nor in subjects without the MetS (HRs 1.34 [1.14-1.57]; p<0.001 and 1.42 [1.24-1.63]; p<0.001, respectively).
Conclusions: We conclude that serum proBNP predicts cardiovascular events independently of established cardiovascular risk factors and of the baseline CAD state both in patients with and in subjects without the MetS.
Poster Hall, Hall C
Saturday, March 18, 2017, 3:45 p.m.-4:30 p.m.
Session Title: Innovations in Cardiovascular Risk Assessment and Reduction
Abstract Category: 32. Prevention: Clinical
Presentation Number: 1235-054
- 2017 American College of Cardiology Foundation